Perimenopause Symptoms: What They Are, When They Start, and What Helps

What Is Perimenopause?

Perimenopause is the hormonal transition period preceding menopause — defined as the phase during which a woman’s ovaries gradually reduce their hormone output before eventually stopping egg release. For most women, perimenopause begins in the mid-to-late 40s, though it can start as early as the late 30s, and lasts anywhere from 2–10 years.

Perimenopause is not a single hormonal event. It is a progressive, variable process in which estrogen and progesterone levels fluctuate irregularly — sometimes dramatically — before eventually declining to the low, stable levels of postmenopause. This hormonal volatility, not simply low estrogen, is the primary driver of perimenopausal symptoms. Many women find the fluctuation phase more symptomatically difficult than postmenopause, when levels stabilize.

When Does Perimenopause Start?

Progesterone typically declines first — often beginning in the late 30s or early 40s, before estrogen shows significant changes. Progesterone decline occurs because anovulatory cycles become more frequent as the ovarian reserve diminishes. Without ovulation, the corpus luteum doesn’t form, and progesterone doesn’t rise in the luteal phase. This creates the “estrogen dominance” pattern characteristic of early perimenopause.

By the mid-to-late 40s, estrogen itself begins to fluctuate. FSH rises as the pituitary attempts to stimulate increasingly resistant ovaries. Estrogen can swing from above-normal to below-normal within the same cycle, producing an erratic symptom picture that many women find confusing and disorienting.

Common Perimenopause Symptoms

Menstrual Changes

Changed cycle length and flow are often the first sign. Cycles may shorten, lengthen, or become irregular. Flow may increase dramatically — driven by the anovulatory estrogen-dominant pattern, in which the uterine lining builds without the shedding trigger of progesterone withdrawal. Missing periods entirely, then having a heavy period, is common.

Hot Flashes and Night Sweats

Hot flashes — sudden waves of heat beginning in the chest and spreading to the face and neck — affect approximately 75% of perimenopausal women. They are more frequent at night, causing sleep disruption that compounds fatigue and cognitive symptoms. The mechanism involves estrogen withdrawal disrupting the hypothalamic temperature regulation center.

Sleep Disruption

Perimenopausal sleep disruption has two distinct mechanisms. Night sweats cause arousal from sleep. Separately, progesterone deficiency reduces GABAergic inhibitory tone — progesterone’s neurosteroid metabolite allopregnanolone directly activates GABA-A receptors. Its deficiency produces anxiety, difficulty initiating sleep, and middle-of-the-night waking that many women describe as feeling “wired” rather than sleepy.

Mood Changes and Cognitive Symptoms

Irritability, anxiety, low mood, and emotional reactivity are among the most disruptive perimenopausal symptoms. Estrogen directly modulates serotonin, dopamine, and GABA receptors throughout the brain. Memory lapses, word-finding difficulty, reduced concentration, and brain fog are reported by 60–70% of perimenopausal women — documented by objective cognitive testing and typically reversible with estrogen stabilization.

Physical Symptoms

Joint pain and stiffness (estrogen has anti-inflammatory effects), breast tenderness, weight gain particularly at the abdomen, heart palpitations, and skin and hair changes are all reported across the perimenopause spectrum.

What Helps

Hormone Therapy

Bioidentical estradiol and micronized progesterone is the most effective treatment for perimenopausal symptoms. Sequential progesterone protocols (10–14 days per month) are typically more appropriate than continuous combined therapy for perimenopausal women. Low-dose estradiol may be added when estrogen levels are inadequate. Testosterone therapy for women — addressing libido, energy, and cognitive symptoms — is an underutilized component of perimenopausal care.

Non-Hormonal Options

SSRIs and SNRIs — particularly paroxetine, venlafaxine, and escitalopram — have demonstrated efficacy for hot flashes and mood symptoms in women who cannot or prefer not to use estrogen. Fezolinetant (Veozah), FDA-approved in 2023, reduces hot flash frequency by targeting the KNDy neurons that drive vasomotor symptoms independently of hormones.

Lifestyle modifications — consistent sleep schedule, aerobic and resistance exercise, reduced alcohol and caffeine, stress reduction — reduce symptom burden but are insufficient as the sole treatment for significant hormonal symptoms. They work best as adjuncts to pharmacological management.

Getting Evaluated for Perimenopause at MultiGen Wellness

A complete perimenopausal evaluation includes estradiol, FSH, LH, progesterone (cycle-phase timed when possible), free and total testosterone, SHBG, complete thyroid panel including TPO antibodies, and metabolic markers. The clinical picture — symptoms, menstrual history, age of onset — combined with lab findings guides the treatment approach. For women who have been tested and told their hormones are “normal” while remaining symptomatic, the distinction between reference-range normal and functionally optimal is a core part of what hormone-focused evaluation provides.